Nasal symptoms

Intranasal anticholinergic agents (e.g., ipratropium) reduce the severity and duration of rhinorrhea but have no effect on other nasal symptoms.11,12,21 Ipratropium reduces cholinergic hyperreactivity and cholinergically mediated histamine- and antigen-induced secretion. Intranasal ipratropium acts locally, with only minimal systemic absorption. Clinical trials demonstrated that ipratropium bromide 0.3% reduced rhinorrhea in adults and children with PAR.11,12 Intranasal ipratropium is an option for patients in whom rhinorrhea is refractory to topical intranasal corticosteroids and/or antihistamines.8,12 Intranasal ipratropium is available only by prescription, and the dose is two sprays nasally two to three times daily.15 Adverse effects are minimal, but dry nasal membranes have been reported.11,12... 

Clinical trials have indicated that omalizumab, a recombinant humanized monoclonal IgE antibody approved for use in moderate to severe persistent asthma in patients with reactivity to a perennial allergen, is effective in the treatment of SAR.25-27 Omalizumab inhibits the binding of IgE to mast cell and basophil receptors, resulting in a reduction of allergic mediator release.25 Additionally, serum free IgE levels are decreased.2 27 In SAR patients, omalizumab improves quality of life and nasal symptoms and reduces antihistamine needs. The most effective dose in SAR appears to be omalizumab 300 mg administered subcutaneously every 3 to 4 weeks depending on baseline IgE levels.26,27... 

A subsequent report by Marttila et al. (1994b) examined the impact of long-term exposure to the same mixture of malodorous sulfur compounds on children from these same three communities. The findings in children, i.e., nasal symptoms and cough, in the most severely polluted community were similar to those reported above and showed increased risks both for the 4-week and the 12-month intervals, although none of these risks reached statistical significance. 

Allergic rhinitis is a risk factor for asthma up to 78% of asthma patients have nasal symptoms, and about 38% of allergic rhinitis patients have asthma. 

Docebenone has shown anti-inflammatory effects in several animal models following local dosing phorbol ester-induced oedema and neutrophil influx in mouse skin [208,209], arachidonate-induced plasma extravasation in rabbit skin [210], the pleural reversed passive Arthus reaction in rats [211], and GPB [212], An oral dose of 80 mg/kg reduced infarct size, LTB4 levels and neutrophil infiltration in a rat myocardial infarction model [213,214], and in a rat brain ischaemia-reperfusion model oedema and LTC4 levels were reduced at 200 mg/kg [107]. Significant, but not dramatic, improvement in nasal symptoms was seen in humans following 150 mg of docebenone twice daily for 8 weeks [215], but there was no effect on bronchial hyperresponsiveness to acetylcholine in asthmatics [216]. 

Nasal symptoms The effectiveness of intranasal cyanocobalamin in patients with nasal congestion, allergic rhinitis, and upper respiratory tract infections has not been determined. Defer treatment until symptoms have subsided. 

Adverse reactions from nasal spray may include dry mouth/throat, epistaxis, headache, nasal dryness, other nasal symptoms, pharyngitis, taste perversion, and upper respiratory tract infection. 

Allergic rhinitis (nasal solution) To prevent and treat allergic rhinitis caused by airborne pollens from trees, grasses, or ragweed, and by mold, animals, and dust. To prevent and relieve the following nasal symptoms Runny/itchy nose, sneezing, and allergic stuffy nose. 

In patients with a known seasonal allergen that precipitates nasal symptoms... 

HIV Adverse reactions occurring in at least 5% of patients include abdominal pain/cramps, anorexia, arthralgia, chills, cough, depression, diarrhea, dizziness, dyspepsia, fatigue, fever, headache, insomnia, malaise, musculoskeletal pain, myalgia, nasal symptoms, nausea, neuropathy, rash, and vomiting. Lab abnormalities may include anemia, neutropenia, thrombocytopenia, and elevations in amylase, AST, ALT, and bilirubin. 

Adverse Reactions Rhinitis and other nasal symptoms Back pain Arthralgia Epistaxis Headache... 

In the active group 3 urticaria, 8 mild asthma, 3 severe asthma, 8 severe nasal symptoms,... 

This study involved 75 patients, 36 in the active group and 36 in the placebo group 3 patients were excluded because of insufficient data. The mean age of patients was 25 years. The study was conducted double-blind versus placebo for 2 years. The criterion for inclusion was rhinitis with or without asthma. The efficacy criteria were skin tests, a diary kept daily of symptoms and treatments, the assessment of nasal symptoms only, assessment of rhinitis using a visual analog scale by the patient and by the doctor, and assay of specific IgE and specific IgG4 versus mites. 

Administration of drug to the therapeutic target site or absorption site in the nasal cavity is the first step in nasal drug delivery. Uniform distribution over the affected area is desirable for the treatment of nasal symptoms, whereas targeting of the favorable absorption sites... 

During the NAC, loratadine was associated with significantly fewer symptoms than placebo at the highest dose of allergen (6250 AUs) (P = 0.04, t = 1.83, df = 19) as well as overall, expressed as the sum of nasal symptom scores experienced over the NAC (P = 0.04, t = 1.83, df = 19). During the NAC, there were no statistically significant differences between Herbal Blend and placebo at any time point (Figure 10.3). 

Figure 10.3 Early-phase nasal symptom scores.

Figure 10.4 Nasal symptom scores during late-phase response. = P = 0.04 for Herbal Blend and placebo areas over NSS curves = P = 0.007 Herbal Blend versus placebo at 6 h.

Figure 10.5 Nasal symptom scores areas over the curve by treatment. = P < 0.05.

Intranasal corticosteroids are effective in reducing ocular symptoms as well as nasal symptoms. The mechanism of action is unclear it may partly be due to a systemic effect resulting from local absorption, although system-ically related adverse effects are uncommon. These are used once or twice daily depending on choice and should be used regularly during the hay fever season. 

Communities near Inhalation "Severely Daily Occurrence of nasal symptoms, cough, Jaakkola ct al. 

Combination therapy of topical and systemic drugs is also an important treatment consideration. When symptoms are isolated to the eye, topical treatment is rapid and most efficient. However, in cases of rhinoconjunctivitis, when nasal symptoms are also present, optimum management includes combining topical ophthalmic medications, olopatadine or ketotifen, for example, with a nasal spray or systemic treatment, such as the oral antihistamine desloratadine. For rhinitis, nasal steroids provide a good treatment option. The above approach targets particular areas of involvement by utilizing the most efficacious route of treatment. 

Abelson MB, Gomes PJ, Vogelson CT, et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies invoking... 

The immunogenicity and safety of inactivated intranasal influenza vaccine have been reviewed (6). The author concluded that the vaccine is highly immunogenic and well tolerated by most vaccinees, in terms of both local nasal symptoms and possible vaccine-mediated systemic symptoms. The symptoms were primarily mild, occasionally moderate, and in a few cases more severe in most cases they lasted for only 1-2 days. 

A 40-year-old woman with no personal or family history of asthma had dyspnea, wheezing, and nasal symptoms for 2 years whenever she used toothpaste and/or ingested mint confections. She had no history of aspirin sensitivity, and a challenge test with a menthol solution diluted in alcohol ruled out any possibihty that the asthma had been caused by preservatives, dyes, or other additives. 

In the treatment of nasal symptoms the patient adjusts the dose so that, perhaps, the theoretical bases of droplet and particle retention are less vital. Although formulation of the nasal drops, or sprays from plastic squeeze-bottles must obviously influence the efficiency of medication, little work has in the past been carried out relating formulation to the effect of intranasal medicines. Microsphere delivery systems have received some attention, however, with special interest being directed to bioadhesive microspheres. 

---